Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD-Reference-Cited by-同舟云学术

Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD

Published:2011-12-16 Issue:14 Volume:118 Page:3565-3570
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Mato Anthony R.,Svoboda Jakub,Feldman Tatyana,Zielonka Tania,Agress Harry,Panush David,Miller Mitchell,Toth Patrick,Lizotte Paul M.,Nasta Sunita,Goldberg Stuart,Chong Emeline,Schuster Steven,Pecora Andrew L.,Goy Andre

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference41 articles.

1. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma;de Guibert;Haematologica.,2006

2. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group;Geisler;Blood.,2008

3. How I treat mantle cell lymphoma;Ghielmini;Blood.,2009

4. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma;Khouri;J Clin Oncol.,1998

5. R-CHOP, followed by high dose therapy and autologous stem cell rescue (HDT/ASCR), and R-HyperCVAD have equivalent progression-free survival and are superior to R-CHOP alone in younger patients with mantle cell lymphoma: a comparative effectiveness analysis from the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project [abstract];LaCasce;Blood.,2009

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?;Journal of Personalized Medicine;2022-07-13

3. Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET/CT in Elderly Mantle Cell Lymphoma;Journal of Clinical Medicine;2022-02-23

4. Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma;Expert Review of Hematology;2021-09-17

5. Mantle cell lymphoma;Critical Reviews in Oncology/Hematology;2020-09